Physician profile
Kabul Singh
NPI 1386602175
$1,917.81
in general payments reported to CMS, 2019-2025
13 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $20.95 · 2021: $354 · 2022: $391 · 2023: $248 · 2024: $532 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.06 | 2019-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $327.10 | 2021-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2021-2024 | Breztri |
| Novo Nordisk INC | $148.31 | 2022 | |
| Intuity Medical INC | $147.30 | 2022 | |
| Amgen INC. | $136.87 | 2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $124.93 | 2023 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $124.75 | 2024 | |
| Boston Scientific Corporation | $121.31 | 2021 | |
| Mallinckrodt Enterprises LLC | $97.00 | 2019 | |
| Abbvie INC. | $22.87 | 2024 | |
| Allergan, INC. | $12.25 | 2019 | |
| Lilly USA, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kabul Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.